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ABSTRACT
Background: Viral hepatitis caused by hepatitis B virus (HBV) is a leading cause of acute 
and chronic liver diseases worldwide.
Objectives: In Italy, a mandatory vaccination policy was introduced in 1991 and was es-
tablished for all newborns and 12-year-old individuals. In 2004, vaccination of 12-year-
old adolescents was discontinued, and that of infants was maintained.
Patients and Methods: We evaluated the seroprevalence of HBV markers in 806 individ-
uals, who were vaccinated at birth or at 12 years of age, to assess the eﬀectiveness of the 
national policy against HBV.
Results: The overall prevalence of anti-HBs antibodies was 90.32% (95% conﬁdence in-
terval [CI]: 88.28–92.36%); 2.23% (95% CI: 1.21–3.25%) of the subjects were positive for both 
antibodies to HBsAg (anti-HBs) and antibodies to hepatitis B core antigen (anti-HBc), 
whereas 5.83% (95% CI 4.21–7.45) of the subjects were negative for all markers tested. 
Further, 1.61% (95% CI: 0.74–2.48%) of the subjects were positive for hepatitis B surface 
antigen (HBsAg).
Conclusions: Our data provide additional evidence that HBV vaccination can confer 
long-term immunity when performed at birth and when performed for healthy ado-
lescents; moreover, the results show the eﬀectiveness of the application of a national 
vaccination strategy.
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approximately 2 billion people worldwide have been 
infected by HBV, more than 350 million are chronically 
infected, and nearly 1 million people die every year from 
acute or chronic sequelae of primary infection with HBV 
(2). The prevalence of HBV-related hepatitis varies across 
nations; in industrialized countries, the prevalence of 
this disease is less than 2% (3). The epidemiology of HBV 
infection in Italy has changed substantially over the last 
few decades. According to the Acute Hepatitis National 
Surveillance System (SEIEVA), the incidence of acute HBV 
decreased from 12 per 100,000 in 1985 to 1.6 per 100,000 in 
2008, with a consequent reduction of HBV-related chron-
1. Background
Hepatitis B virus (HBV) contributes to most of the 
hepatitis disease burden worldwide (1). After an acute 
infection, 1–10% of healthy adults and 30–90% of infected 
children become chronic carriers. WHO estimates that Hepat Mon. 2011;11(9):750-752
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ic hepatic diseases from 50% to 13% (4). This decrease in 
incidence was a consequence of the improvement of hy-
giene and socioeconomic conditions; campaigns for the 
prevention of the spread of HIV infection, which has the 
same route of transmission as HBV; introduction of the 
mandatory vaccination policy in 1991 for all newborns 
and 12-year-old adolescents; and mandatory screening 
for women in the third quarter of pregnancy (5).
In 2004, the vaccination of 12-year-old adolescents was 
discontinued, and that of infants was maintained. The 
objective of this vaccination strategy was to achieve a 
protection rate of 95% among the population in the age 
range of 0–24 years by 2003, thereby rendering the vac-
cination mandatory only for newborns and scheduling 
passive immunization within the ﬁrst 24 hours of life; 
moreover, the strategy aimed to administer the ﬁrst dose 
of vaccine to newborns whose mothers were seropositive 
for hepatitis B surface antigen (HBsAg) (6). 
2. Objectives
The purpose of this study was to evaluate the seropreva-
lence of markers for HBV among a group of individuals 
submitted to the Italian vaccination strategy (at birth 
and at the age of 12 years, born between 1979 and 2010) 
to assess the eﬀectiveness of the application of HBV vac-
cination strategy and the critical aspects and priorities 
of intervention.
3. Patients and Methods
The study population consisted of 806 individuals (372 
male and 434 female individuals) admitted consecutively 
to the Diagnostic Service of the University Hospital of Ca-
gliari–Monserrato. In this study, we enrolled all subjects 
in the 2 cohorts involved in the HBV national mandatory 
vaccination strategy; the ﬁrst cohort comprised subjects 
who were born after 1991 and were vaccinated at birth 
(n = 57), and the second cohort comprised subjects who 
were born between 1979 and 1991 and were vaccinated at 
the age of 12 years (n = 749); the median age of the sub-
jects was 25.47 years. Enrolment was carried out between 
2005 and 2010 to obtain a representative sample. The 
study protocol did not include a control group, because 
virtually, the entire Italian population that belonged to 
the same age group had been vaccinated (7). All the 806 
individuals enrolled in the study gave their written in-
formed consent for participation; 0.86% (7/813) of the to-
tal number of the subjects recruited for the study did not 
agree to participate. Blood samples were obtained for all 
the subjects, and sera were collected and maintained at 
-20°C to measure the concentration of HBV serological 
markers (i.e., HBsAg, antibodies to HBsAg [anti-HBs], and 
antibodies to hepatitis B core antigen [anti-HBc]). We 
employed an immunoenzymatic commercial kit, AxSYM 
(Abbott).
Individuals with anti-HBs titers ≥ 10 mIU/mL were con-
sidered immunized by vaccination, whereas those with 
antibody titers < 10 mIU/mL were considered nonim-
mune. For those individuals who tested positive for HB-
sAg, a retrospective clinical history was collected to in-
vestigate the presence of risk factors and possible causes 
of infection. Diﬀerences in the frequency of hepatitis 
were detected by the Chi-Square test, and a P < 0.05 was 
considered signiﬁcant. The 95% conﬁdence interval (CI) 
for geometric mean titers and frequency of the disease 
was also calculated.
4. Results
Among the 806 individuals who were vaccinated either 
at birth or at the age of 12 years, the overall prevalence 
of anti-HBs antibodies was 90.32% (95% CI: 88.28–92.36). 
Moreover, 2.23% (95% CI: 1.21–3.25%) of the subjects were 
positive for both anti-HBs and anti-HBc antibodies (all of 
these subjects were from the 12-year-old cohort), whereas 
5.83% (95% CI: 4.21–7.45) of the subjects were negative for 
all the markers tested. The rate of negative test results for 
all the markers was higher in the ﬁrst cohort (12.5%) than 
in the second cohort (5.42%; Chi-Square test, P = 0.062). 
Positive test results for HBsAg were obtained for 1.61% (n 
= 13; 95% CI: 0.74–2.48) of the subjects (Figure 1). In the ﬁrst 
cohort, 1 subject was positive for HBsAg; he was born to 
an HBsAg- and HIV-positive mother, and at birth, he was 
not submitted to an active-passive immunoprophylaxis 
policy established by the Italian legislation. In the sec-
ond cohort, we found 12 subjects tested positive for HB-
sAg: 4 individuals were known to be HBsAg carriers at 
the time of vaccination proposal (3 were born to HBsAg-
positive mothers; 1 was born in Romania, an endemic 
area for HBV infection, and was later adopted by Italian 
parents). Four individuals had been vaccinated and were 
subsequently identiﬁed as HBsAg carriers (1 lived with an 
HBsAg-positive mother, and the other 3 were not exposed 
to any known risk factors for HBV infection). One subject 
was tested positive for both HBsAg and HIV, but lacked 
further history pertaining to vaccination or risk factors; 
moreover, we could not obtain the clinical history of the 
other 3 individuals. Gender did not have an inﬂuence on 
HBcAb+, HBsAb+, HBsAg-  HBcAb+, HBsAb-, HBsAg+ 
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Figure 1. Prevalence of HBV Markers among the 806 Subjects.Hepat Mon. 2011;11(9):750-752
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the seroprevalence of anti-HBsAg antibodies (data not 
shown).
 5. Discussion
The present study showed a high seroprevalence of an-
ti-HBs antibodies owing to vaccination, with persistence 
of antibodies even beyond 10 years after vaccination. The 
proportion of individuals tested negative for anti-HBs 
antibodies observed in this study may be attributed to 
a loss of antibody concentration that can occur many 
years after vaccination; nevertheless, these individuals 
could be considered protected against HBV infection, 
as conﬁrmed by recent scientiﬁc studies. Indeed, immu-
nological memory for HBsAg is maintained even after 
the loss of anti-HBsAg antibodies, thereby providing ef-
fective protection against acute hepatitis and the de-
velopment of the HBsAg carrier state (7-9). These results 
conﬁrm the eﬃcacy of the mandatory Italian policy on 
immunization against HBV and its epidemiological im-
pact, previously reported in 1998 with a coverage range 
at 24 months of age in Italy (85.6%–100%) and in our re-
gion (95.2%) (10). Overall, the prevalence rate of anti-HBs 
antibodies is in agreement with the results of similar 
surveys (7). The percentage of anti-HBs- and anti-HBc-
positive individuals suggests that an infection occurred 
after vaccination; however, this infection did not develop 
into a chronic disease owing to the vaccine-induced anti-
HBsAg antibodies. Although our study was undertaken 
in a low endemicity country, these data along with the 
lower proportion of seronegative subjects in the second 
cohort than in the ﬁrst cohort, despite the lack of signiﬁ-
cant diﬀerence between the 2 cohorts, suggest the possi-
bility of a natural booster eﬀect in vaccinated subjects in 
our region as well as in those living in regions of higher 
endemicity.
Our data show that in a substantial proportion of cases, 
HBsAg-positive individuals were already infected at the 
time of proposal of the vaccination policy. Seroconver-
sion of individuals to HBsAg-positive individuals after 
vaccination is probably attributed to a pre-existing un-
known infection at the time of vaccination and not nec-
essarily to breakthrough infections. However, the fact 
that these individuals were included in the cohort im-
plies the absence of vaccination at birth (because vacci-
nation was not mandatory at that time) and inadequate 
vaccination because of their pre-existing unknown infec-
tions. Our study has some strengths and limitations; ex-
ternal validity allows the comparison of the eﬀectiveness 
of vaccination campaigns evaluated by studies in other 
Italian regions as well as the identiﬁcation of regional/
local diﬀerences in the application and eﬀectiveness of 
Italian vaccination policies. The main limitation of our 
study is the collection of incomplete history for some in-
dividuals who were positive for HBsAg.
In conclusion, our data provide additional evidence that 
HBV vaccination can confer long-term immunity when 
performed at birth and also when performed for healthy 
adolescents (8-10). Furthermore, this study showed the 
eﬀectiveness and the need to apply the national vacci-
nation campaign in the city of Cagliari. This study also 
highlighted the importance of a correct and exhaustive 
data collection procedure in a local surveillance system, 
to conduct surveys on the eﬀectiveness of public health 
interventions. Data collection and analysis can also be 
useful to identify critical aspects, priorities, and further 
targeted interventions as well as to facilitate appropriate 
allocation of local health resources.
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